Adams Kendra has filed 23 insider transactions across 1 company since February 2024.
Most recent transaction: a option exercise of 30950 shares of C4 Therapeutics, Inc. ($CCCC) on February 14, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 14, 2026 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | M | Common Stock | 30950 | $0.00 | 400,479.0000 | 96,914,418 | 8.38% | 0.03% |
| Feb. 13, 2026 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | F | Common Stock | 1863 | $1.89 | 400,479.0000 | 96,914,418 | 0.46% | 0.00% |
| Feb. 13, 2026 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | A | Common Stock | 240000 | $0.00 | 402,342.0000 | 96,914,418 | 147.84% | 0.25% |
| Feb. 13, 2026 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | M | Common Stock | 3750 | $0.00 | 402,342.0000 | 96,914,418 | 0.94% | 0.00% |
| Feb. 14, 2026 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | F | Common Stock | 15381 | $1.89 | 385,098.0000 | 96,914,418 | 3.84% | 0.02% |
| Sept. 18, 2025 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | M | Common Stock | 6250 | $0.00 | 165,117.0000 | 70,989,661 | 3.93% | 0.01% |
| Sept. 18, 2025 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | F | Common Stock | 2775 | $3.32 | 162,342.0000 | 70,989,661 | 1.68% | 0.00% |
| Feb. 13, 2025 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | F | Common Stock | 1863 | $3.20 | 82,576.0000 | 0 | 2.21% | 0.00% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | A | Common Stock | 87100 | $0.00 | 169,676.0000 | 0 | 105.48% | 0.00% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | F | Common Stock | 4559 | $3.18 | 165,117.0000 | 0 | 2.69% | 0.00% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | A | Stock Option (Right to Buy) | 130600 | $0.00 | 130,600.0000 | 0 | 9999.99% | 0.00% |
| Nov. 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | M | Common Stock | 3750 | $0.00 | 85,541.0000 | 0 | 4.58% | 0.00% |
| Nov. 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | F | Common Stock | 1102 | $6.04 | 84,439.0000 | 0 | 1.29% | 0.00% |
| Nov. 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | M | Performance Restricted Stock Units | 3750 | $0.00 | 10,500.0000 | 0 | 26.32% | 0.00% |
| Sept. 18, 2024 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | F | Common Stock | 1837 | $6.38 | 81,791.0000 | 0 | 2.20% | 0.00% |
| Sept. 16, 2024 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | F | Common Stock | 661 | $6.36 | 83,628.0000 | 0 | 0.78% | 0.00% |
| Sept. 16, 2024 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | M | Performance Restricted Stock Units | 2250 | $0.00 | 14,250.0000 | 0 | 13.64% | 0.00% |
| Sept. 16, 2024 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | M | Common Stock | 2250 | $0.00 | 84,289.0000 | 0 | 2.74% | 0.00% |
| March 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | A | Stock Option (Right to Buy) | 45000 | $0.00 | 45,000.0000 | 0 | 9999.99% | 0.00% |
| March 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | D | Stock Option (Right to Buy) | 45000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 14, 2024 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | A | Stock Option (Right to Buy) | 165300 | $0.00 | 165,300.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2024 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | A | Common Stock | 36700 | $0.00 | 82,039.0000 | 0 | 80.95% | 0.00% |
| Feb. 13, 2024 | C4 Therapeutics, Inc. | $CCCC | Adams Kendra | Chief Financial Officer | F | Common Stock | 1301 | $6.53 | 45,339.0000 | 0 | 2.79% | 0.00% |